ebomi
Colour theme
Sign in
Insider · CIK 0001618789

Vivo Capital VIII, LLC

CIK 0001618789 Name as filed on the most recent filing

Filed as Vivo Capital VIII, LLC (24)

90 transaction lines · from 24 filings · filed 2017-09-18 to 2024-04-03 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

5 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-21 05:23 UTC.

Transactions filed by this insider
Direction Date Issuer Code Shares Price Value USD Filing
2024-04-03 Terns Pharmaceuticals, Inc.
TERN 		S, Open-market sale 103,870 disposed 6.20 643,994.00 Form 4, filing 0001213900-24-030020
2024-04-03 Terns Pharmaceuticals, Inc.
TERN 		S, Open-market sale 30,047 disposed 6.20 186,291.40 Form 4, filing 0001213900-24-030020
2024-04-03 Terns Pharmaceuticals, Inc.
TERN 		S, Open-market sale 4,149 disposed 6.20 25,723.80 Form 4, filing 0001213900-24-030020
2024-04-02 Terns Pharmaceuticals, Inc.
TERN 		S, Open-market sale 76,346 disposed 6.65 507,700.90 Form 4, filing 0001213900-24-030020
2024-04-02 Terns Pharmaceuticals, Inc.
TERN 		S, Open-market sale 22,084 disposed 6.65 146,858.60 Form 4, filing 0001213900-24-030020
2024-04-02 Terns Pharmaceuticals, Inc.
TERN 		S, Open-market sale 3,050 disposed 6.65 20,282.50 Form 4, filing 0001213900-24-030020
2024-04-01 Terns Pharmaceuticals, Inc.
TERN 		S, Open-market sale 136,255 disposed 6.99 952,422.45 Form 4, filing 0001213900-24-030020
2024-04-01 Terns Pharmaceuticals, Inc.
TERN 		S, Open-market sale 39,411 disposed 6.99 275,482.89 Form 4, filing 0001213900-24-030020
2024-04-01 Terns Pharmaceuticals, Inc.
TERN 		S, Open-market sale 5,451 disposed 6.99 38,102.49 Form 4, filing 0001213900-24-030020
2023-12-19 Impel Pharmaceuticals Inc
IMPL 		S, Open-market sale 208,657 disposed 0.08 16,692.56 Form 4, filing 0001213900-23-097043
2023-12-19 Impel Pharmaceuticals Inc
IMPL 		S, Open-market sale 28,632 disposed 0.08 2,290.56 Form 4, filing 0001213900-23-097043
2023-12-18 Impel Pharmaceuticals Inc
IMPL 		S, Open-market sale 209,029 disposed 0.11 22,993.19 Form 4, filing 0001213900-23-097043
2023-12-18 Impel Pharmaceuticals Inc
IMPL 		S, Open-market sale 28,682 disposed 0.11 3,155.02 Form 4, filing 0001213900-23-097043
2023-12-15 Impel Pharmaceuticals Inc
IMPL 		S, Open-market sale 87,934 disposed 0.29 25,500.86 Form 4, filing 0001213900-23-097043
2023-12-15 Impel Pharmaceuticals Inc
IMPL 		S, Open-market sale 12,066 disposed 0.29 3,499.14 Form 4, filing 0001213900-23-097043
2023-11-21 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 1,707 disposed 0.90 1,536.30 Form 4, filing 0001213900-23-089692
2023-11-21 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 1,457 disposed 0.90 1,311.30 Form 4, filing 0001213900-23-089692
2023-11-21 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 236 disposed 0.90 212.40 Form 4, filing 0001213900-23-089692
2023-11-20 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 27,465 disposed 0.92 25,267.80 Form 4, filing 0001213900-23-088909
2023-11-20 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 23,443 disposed 0.92 21,567.56 Form 4, filing 0001213900-23-088909
2023-11-20 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 3,792 disposed 0.92 3,488.64 Form 4, filing 0001213900-23-088909
2023-11-17 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 8,211 disposed 0.93 7,636.23 Form 4, filing 0001213900-23-088909
2023-11-17 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 7,009 disposed 0.93 6,518.37 Form 4, filing 0001213900-23-088909
2023-11-17 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 1,134 disposed 0.93 1,054.62 Form 4, filing 0001213900-23-088909
2023-11-16 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 7,531 disposed 0.96 7,229.76 Form 4, filing 0001213900-23-088909
2023-11-16 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 6,429 disposed 0.96 6,171.84 Form 4, filing 0001213900-23-088909
2023-11-16 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 1,040 disposed 0.96 998.40 Form 4, filing 0001213900-23-088909
2022-12-23 Terns Pharmaceuticals, Inc.
TERN 		P, Open-market purchase 758,620 acquired 7.25 5,499,995.00 Form 4, filing 0001213900-22-082664
2022-09-07 Terns Pharmaceuticals, Inc.
TERN 		P, Open-market purchase 600,000 acquired 3.60 2,160,000.00 Form 4, filing 0001213900-22-054888
2022-08-16 Terns Pharmaceuticals, Inc.
TERN 		P, Open-market purchase 1,500,000 acquired 2.42 3,630,000.00 Form 4, filing 0001213900-22-048763
2022-08-15 Terns Pharmaceuticals, Inc.
TERN 		P, Open-market purchase 1,218 acquired 2.99 3,641.82 Form 4, filing 0001213900-22-048763
2022-08-12 Terns Pharmaceuticals, Inc.
TERN 		P, Open-market purchase 1,123,021 acquired 2.98 3,346,602.58 Form 4, filing 0001213900-22-048763
2021-04-27 Impel Neuropharma Inc
IMPL 		P, Open-market purchase 505,620 acquired 15.00 7,584,300.00 Form 4, filing 0001213900-21-023652
2021-04-27 Impel Neuropharma Inc
IMPL 		P, Open-market purchase 69,380 acquired 15.00 1,040,700.00 Form 4, filing 0001213900-21-023652
2021-02-09 Terns Pharmaceuticals, Inc.
TERN 		P, Open-market purchase 357,353 acquired 17.00 6,075,001.00 Form 4, filing 0001567619-21-002591
2021-02-09 Terns Pharmaceuticals, Inc.
TERN 		P, Open-market purchase 103,372 acquired 17.00 1,757,324.00 Form 4, filing 0001567619-21-002591
2021-02-09 Terns Pharmaceuticals, Inc.
TERN 		P, Open-market purchase 14,275 acquired 17.00 242,675.00 Form 4, filing 0001567619-21-002591
2021-02-09 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 144 disposed 20.00 2,880.00 Form 4, filing 0001209191-21-008758
2021-02-09 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 62 disposed 20.00 1,240.00 Form 4, filing 0001209191-21-008758
2021-02-09 Bolt Biotherapeutics, Inc.
BOLT 		S, Open-market sale 20 disposed 20.00 400.00 Form 4, filing 0001209191-21-008758
2021-02-09 Bolt Biotherapeutics, Inc.
BOLT 		P, Open-market purchase 175,733 acquired 20.00 3,514,660.00 Form 4, filing 0001209191-21-008758
2021-02-09 Bolt Biotherapeutics, Inc.
BOLT 		P, Open-market purchase 150,000 acquired 20.00 3,000,000.00 Form 4, filing 0001209191-21-008758
2021-02-09 Bolt Biotherapeutics, Inc.
BOLT 		P, Open-market purchase 24,267 acquired 20.00 485,340.00 Form 4, filing 0001209191-21-008758
2020-10-20 Aligos Therapeutics, Inc.
ALGS 		P, Open-market purchase 483,267 acquired 15.00 7,249,005.00 Form 4, filing 0001567619-20-018010
2020-10-20 Aligos Therapeutics, Inc.
ALGS 		P, Open-market purchase 66,733 acquired 15.00 1,000,995.00 Form 4, filing 0001567619-20-018010
2020-04-17 Crinetics Pharmaceuticals, Inc.
CRNX 		S, Open-market sale 74,333 disposed 15.40 1,144,728.20 Form 4, filing 0001213900-20-009500
2020-04-17 Crinetics Pharmaceuticals, Inc.
CRNX 		S, Open-market sale 10,265 disposed 15.40 158,081.00 Form 4, filing 0001213900-20-009500
2020-04-16 Crinetics Pharmaceuticals, Inc.
CRNX 		S, Open-market sale 26,527 disposed 15.20 403,210.40 Form 4, filing 0001213900-20-009500
2020-04-16 Crinetics Pharmaceuticals, Inc.
CRNX 		S, Open-market sale 3,663 disposed 15.20 55,677.60 Form 4, filing 0001213900-20-009500
2020-04-15 Crinetics Pharmaceuticals, Inc.
CRNX 		S, Open-market sale 189,625 disposed 15.50 2,939,187.50 Form 4, filing 0001213900-20-009500

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase

Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 2
  • Open-market sale 3
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Vivo Capital VIII, LLC, insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001618789

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.